Pluri Inc
NASDAQ:PLUR

Watchlist Manager
Pluri Inc Logo
Pluri Inc
NASDAQ:PLUR
Watchlist
Price: 4.5501 USD -5.6% Market Closed
Market Cap: 25.3m USD
Have any thoughts about
Pluri Inc?
Write Note

Pluri Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pluri Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Pluri Inc
NASDAQ:PLUR
Revenue
$598k
CAGR 3-Years
N/A
CAGR 5-Years
64%
CAGR 10-Years
5%
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Revenue
$11m
CAGR 3-Years
21%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Revenue
$158.4m
CAGR 3-Years
26%
CAGR 5-Years
2%
CAGR 10-Years
8%
Urogen Pharma Ltd
NASDAQ:URGN
Revenue
$89.4m
CAGR 3-Years
31%
CAGR 5-Years
437%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Revenue
$99k
CAGR 3-Years
-46%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Revenue
â‚Ş0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pluri Inc
Glance View

Market Cap
25.1m USD
Industry
Biotechnology

Pluri Inc is a IL-based company operating in Biotechnology industry. Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

PLUR Intrinsic Value
1.4197 USD
Overvaluation 69%
Intrinsic Value
Price

See Also

What is Pluri Inc's Revenue?
Revenue
598k USD

Based on the financial report for Sep 30, 2024, Pluri Inc's Revenue amounts to 598k USD.

What is Pluri Inc's Revenue growth rate?
Revenue CAGR 10Y
5%

Over the last year, the Revenue growth was 135%.

Back to Top